Prime Medicine, Inc. Operating Expenses
Prime Medicine, Inc. (PRME) reported Operating Expenses of $44.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Prime Medicine, Inc. operating expenses for the quarter ending 2026-06-30 was $44.44M, a 18.45% decline year-over-year.
- Prime Medicine, Inc. operating expenses for the quarter ending 2026-03-31 was $51.51M, a 4.34% decline year-over-year.
- Prime Medicine, Inc. operating expenses for the quarter ending 2025-12-31 was $49.45M, a 6.55% increase year-over-year.
- Prime Medicine, Inc. operating expenses for the quarter ending 2025-09-30 was $55.20M, a 1.39% increase year-over-year.
- Prime Medicine, Inc. operating expenses for fiscal 2025 was $212.98M, a 3.67% increase from fiscal 2024.
- Prime Medicine, Inc. operating expenses for fiscal 2024 was $205.45M, a 0.32% increase from fiscal 2023.
- Prime Medicine, Inc. operating expenses for fiscal 2023 was $204.79M, a 75.72% increase from fiscal 2022.
- Prime Medicine, Inc. operating expenses for fiscal 2022 was $116.54M, a 37.96% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.44M 10-Q · filed 2026-08-06 | $95.95M 10-Q · filed 2026-08-06 | $145.40M derived: sum of 3 quarters · filed 2026-08-06 | $200.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.51M 10-Q · filed 2026-05-07 | $100.96M derived: sum of 2 quarters · filed 2026-05-07 | $156.15M derived: sum of 3 quarters · filed 2026-05-07 | $210.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $49.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $104.64M derived: sum of 2 quarters · filed 2026-03-03 | $159.14M derived: sum of 3 quarters · filed 2026-08-06 | $212.98M 10-K · filed 2026-03-03 |
| 2025-09-30 | $55.20M 10-Q · filed 2025-11-07 | $109.69M derived: sum of 2 quarters · filed 2026-08-06 | $163.54M 10-Q · filed 2025-11-07 | $209.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $54.49M 10-Q · filed 2026-08-06 | $108.34M 10-Q · filed 2026-08-06 | $154.74M derived: sum of 3 quarters · filed 2026-08-06 | $209.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $53.85M 10-Q · filed 2026-05-07 | $100.25M derived: sum of 2 quarters · filed 2026-05-07 | $154.69M derived: sum of 3 quarters · filed 2026-05-07 | $210.36M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $46.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $100.85M derived: sum of 2 quarters · filed 2026-03-03 | $156.52M derived: sum of 3 quarters · filed 2026-03-03 | $205.45M 10-K · filed 2026-03-03 |
| 2024-09-30 | $54.44M 10-Q · filed 2025-11-07 | $110.11M derived: sum of 2 quarters · filed 2025-11-07 | $159.04M 10-Q · filed 2025-11-07 | $227.09M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $55.67M 10-Q · filed 2025-08-07 | $104.60M 10-Q · filed 2025-08-07 | $172.65M derived: sum of 3 quarters · filed 2025-08-07 | $224.11M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $48.93M 10-Q · filed 2025-05-08 | $116.97M derived: sum of 2 quarters · filed 2025-05-08 | $168.43M derived: sum of 3 quarters · filed 2025-05-08 | $213.69M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $68.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $119.50M derived: sum of 2 quarters · filed 2025-02-28 | $164.76M derived: sum of 3 quarters · filed 2025-02-28 | $204.79M 10-K · filed 2025-02-28 |
| 2023-09-30 | $51.46M 10-Q · filed 2024-11-12 | $96.72M derived: sum of 2 quarters · filed 2024-11-12 | $136.75M 10-Q · filed 2024-11-12 | $175.44M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $45.26M 10-Q · filed 2024-08-08 | $85.29M 10-Q · filed 2024-08-08 | $123.98M derived: sum of 3 quarters · filed 2024-08-08 | $155.63M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $40.03M 10-Q · filed 2024-05-10 | $78.72M derived: sum of 2 quarters · filed 2024-05-10 | $110.37M derived: sum of 3 quarters · filed 2024-05-10 | $136.68M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $38.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $70.34M derived: sum of 2 quarters · filed 2024-03-01 | $96.65M derived: sum of 3 quarters · filed 2024-03-01 | $116.54M 10-K · filed 2024-03-01 |
| 2022-09-30 | $31.66M 10-Q · filed 2023-11-03 | $57.96M derived: sum of 2 quarters · filed 2023-11-03 | $77.86M 10-Q · filed 2023-11-03 | $137.93M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $26.30M 10-Q · filed 2023-08-07 | $46.20M 10-Q · filed 2023-08-07 | $106.28M derived: sum of 3 quarters · filed 2023-08-07 | $116.71M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $19.90M 10-Q · filed 2023-05-11 | $79.97M derived: sum of 2 quarters · filed 2023-05-11 | $90.40M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $60.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $70.50M derived: sum of 2 quarters · filed 2023-03-09 | $84.47M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $10.43M 10-Q · filed 2022-11-14 | $24.40M 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $6.14M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |